PriceTargets.com logo

Seelos Therapeutics - SEEL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.33
  • Forecasted Upside: 1,105.86%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.19 As of 10/2/2023 01:00 AM ET
▲ +0.01 (5.45%)

This chart shows the closing price for SEEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seelos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SEEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SEEL

Analyst Price Target is $2.33
▲ +1,105.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Seelos Therapeutics in the last 3 months. The average price target is $2.33, with a high forecast of $4.00 and a low forecast of $1.00. The average price target represents a 1,105.86% upside from the last price of $0.19.

This chart shows the closing price for SEEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Seelos Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2023GuggenheimDowngradeBuy ➝ NeutralLow
9/21/2023BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$4.00 ➝ $1.00Low
9/20/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$2.00Low
8/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$2.00Low
5/16/2023Cantor FitzgeraldLower Target$3.00 ➝ $2.00Low
5/15/2023BTIG ResearchLower Target$11.00 ➝ $4.00Low
3/24/2023BenchmarkLower Target$6.00 ➝ $4.00Low
6/6/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/14/2022B. RileyLower TargetBuy$6.00 ➝ $4.00High
1/24/2022B. RileyLower Target$11.00 ➝ $6.00High
9/27/2021Roth CapitalUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
8/18/2021B. RileyLower TargetBuy$15.00 ➝ $11.00Medium
8/10/2021Roth CapitalLower TargetNeutral$4.00 ➝ $2.50High
7/1/2021GuggenheimInitiated CoverageBuy$8.00High
6/1/2021Cantor FitzgeraldInitiated CoverageOverweight$10.00High
5/17/2021Roth CapitalDowngradeBuy ➝ NeutralHigh
3/30/2021B. RileyInitiated CoverageBuy$15.00High
3/11/2021BTIG ResearchInitiated CoverageBuy$14.00High
9/28/2020Roth CapitalReiterated RatingBuy$12.00High
6/23/2020Roth CapitalBoost TargetBuy$8.00 ➝ $12.00High
11/18/2019HC WainwrightBoost TargetBuy$2.00 ➝ $4.00High
11/14/2019BenchmarkInitiated CoverageBuy$4.00High
8/2/2019Roth CapitalSet TargetBuy$8.00Low
5/14/2019Roth CapitalInitiated CoverageBuy ➝ Buy$8.00High
5/10/2019HC WainwrightInitiated CoverageBuy$4.00High
(Data available from 10/3/2018 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
3/7/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/5/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
Mentions as of
10/3/2023

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Seelos Therapeutics logo
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.19
Low: $0.19
High: $0.20

50 Day Range

MA: $1.05
Low: $0.16
High: $1.58

52 Week Range

Now: $0.19
Low: $0.15
High: $1.66

Volume

5,567,472 shs

Average Volume

9,857,309 shs

Market Capitalization

$24.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Seelos Therapeutics?

The following sell-side analysts have issued stock ratings on Seelos Therapeutics in the last year: Benchmark Co., BTIG Research, Cantor Fitzgerald, and Guggenheim.
View the latest analyst ratings for SEEL.

What is the current price target for Seelos Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Seelos Therapeutics in the last year. Their average twelve-month price target is $2.33, suggesting a possible upside of 1,105.9%. BTIG Research has the highest price target set, predicting SEEL will reach $4.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $1.00 for Seelos Therapeutics in the next year.
View the latest price targets for SEEL.

What is the current consensus analyst rating for Seelos Therapeutics?

Seelos Therapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SEEL, but not buy more shares or sell existing shares.
View the latest ratings for SEEL.

What other companies compete with Seelos Therapeutics?

Other companies that are similar to Seelos Therapeutics include Synlogic, Vallon Pharmaceuticals, Indaptus Therapeutics, Sensei Biotherapeutics and Lumos Pharma. Learn More about companies similar to Seelos Therapeutics.

How do I contact Seelos Therapeutics' investor relations team?

Seelos Therapeutics' physical mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company's listed phone number is (646) 293-2100 and its investor relations email address is anthony.marcian[email protected]. The official website for Seelos Therapeutics is www.seelostherapeutics.com. Learn More about contacing Seelos Therapeutics investor relations.